266 related articles for article (PubMed ID: 31981264)
1. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
3. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
[TBL] [Abstract][Full Text] [Related]
4. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
[TBL] [Abstract][Full Text] [Related]
5. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
Huang CF; Kuo HT; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Chen CY; Tseng KC; Yu ML
Sci Rep; 2021 Dec; 11(1):23473. PubMed ID: 34873250
[TBL] [Abstract][Full Text] [Related]
6. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
[TBL] [Abstract][Full Text] [Related]
7. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
Yap DYH; Liu KSH; Hsu YC; Wong GLH; Tsai MC; Chen CH; Hsu CS; Hui YT; Li MKK; Liu CH; Kan YM; Yu ML; Yuen MF
Clin Mol Hepatol; 2020 Oct; 26(4):554-561. PubMed ID: 32854457
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
[TBL] [Abstract][Full Text] [Related]
10. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
11. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
Hsu SJ; Chiu MC; Fang YJ; Yang TH; Yu JJ; Chen CC; Kuo CC; Lee JY; Chen CH; Chen DS; Kao JH
J Formos Med Assoc; 2019 Aug; 118(8):1187-1192. PubMed ID: 31279502
[TBL] [Abstract][Full Text] [Related]
13. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
[TBL] [Abstract][Full Text] [Related]
15. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
Ruwayni AA; AlObary EE; Alyahya KM
Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
18. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ; Brown A; Dylla DE; Dillon JF; Luetkemeyer AF; Feld JJ; Mutimer D; Ghalib R; Crown E; Lovell SS; Hu Y; Moreno C; Nelson DR; Colombo M; Papatheodoridis G; Rockstroh JK; Skoien R; Lawitz E; Jacobson IM
Am J Gastroenterol; 2021 Sep; 116(9):1896-1904. PubMed ID: 34465693
[TBL] [Abstract][Full Text] [Related]
19. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Cornberg M; Stoehr A; Naumann U; Teuber G; Klinker H; Lutz T; Möller H; Hidde D; Lohmann K; Simon KG
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891520
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal.
Vera J; Gomes A; Póvoas D; Seixas D; Maltez F; Pedroto I; Maia L; Mota M; Vieira MJ; Manata MJ; Ferreira P; Lino S; Pereira Guedes T; Barradas V; Marques N
Acta Med Port; 2024 May; 37(5):323-333. PubMed ID: 38325411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
